Previous 10 | Next 10 |
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1 p.m. London time (8 a.m. EDT). The Company will release its second-quarter 2022 results prior...
Harris Associates’ 13F portfolio value increased from $64.23B to $75.90B this quarter. They increased Charter Communications, General Motors, Amazon.com, and Netflix while reducing Humana, Hilton Worldwide, and General Dynamics. The top three positions are Alphabet, Fiserv,...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election was part of the LivaNova 2022 Annual General Meeting of Shareholders (AGM) held on June 1...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald, Chief Executive Officer, will present in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California. The presen...
David Einhorn's 13F stock portfolio value decreased from $1.75B to $1.57B this quarter. Greenlight increased Chemours, Warner Bros. Discovery, Resideo, LivaNova, Kyndryl, and PLBY while dropping Jack in the Box and EchoStar. They also added Southwestern Energy, Weatherford plc, Intern...
LivaNova is seeing success in cardiopulmonary, thanks to a weak 2021 and a return to normal. Neuromodulation is being driven by replacements rather than new implants, which is a bit of a growth concern. LivaNova's margins aren't advancing in neuromodulation either. But the big...
Our portfolio has eclipsed all benchmarks both on a YoY and YTD basis with our contrarian, obscure stock and mid-cap approach with an exaggerated risk aversion. We discuss the logic behind our general style and why it is structurally advantaged against indices, and how it contributed ...
LivaNova PLC (LIVN) Q1 2022 Results Earnings Conference Call May 4, 2022, 08:00 AM ET Company Participants Matthew Dodds - Senior Vice President, Corporate Development Damien McDonald - Chief Executive Officer Alex Shvartsburg - Chief Financial Officer Conference Call Participants Rick Wise -...
The following slide deck was published by LivaNova PLC in conjunction with their 2022 Q1 earnings call. For further details see: LivaNova PLC 2022 Q1 - Results - Earnings Call Presentation
LivaNova PLC press release (NASDAQ:LIVN): Q1 Non-GAAP EPS of $0.48 in-line. Revenue of $240.2M (-3.0% Y/Y) beats by $8.63M. LivaNova continues to expect worldwide net sales for full-year 2022 to grow between 3 and 5 percent on a constant-currency basis after excluding the impact of the Heart ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 00:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. ...
2024-06-06 11:00:14 ET Rick Wise from Stifel Nicolaus issued a price target of $70.00 for LIVN on 2024-06-06 09:52:00. The adjusted price target was set to $70.00. At the time of the announcement, LIVN was trading at $53.16. The overall price target consensus is at $69.5...